A 49-year-old patient sat across from me last Tuesday and finally said the sentence she had been rehearsing for months: sex had become painful, she had been avoiding it for over a year, and she was starting to wonder if her marriage was going to survive what she did not have language for. She had brought it up with her primary care provider eighteen months earlier and been told to "try lubricant." She had brought it up with her gynecologist a year before that and been told it was "just menopause." Neither person had asked what kind of pain, where it was located, when it started, or what made it worse. Neither had run a single relevant lab.
Painful intercourse — dyspareunia — is one of the most undertreated complaints in mid-life clinical care. It is also one of the most diagnosable, once someone takes a structured history. The reason it persists for years is not that the underlying causes are mysterious. It is that the conversation rarely happens at the depth it requires.
What kind of pain — the question that has to come first
The single most useful diagnostic question is one most patients have never been asked: what kind of pain, and where. The answer narrows the differential dramatically.
Pain at the vaginal opening on initial penetration that resolves once intercourse continues is the classic pattern of genitourinary syndrome of menopause (GSM). The tissues at the introitus thin and dry as estrogen declines; the friction at first contact is what hurts. This is the most common pattern I see in perimenopausal and postmenopausal women.
Pain that is positional or deep — felt with deep penetration, worse in certain positions, sometimes radiating to the lower back — is a different problem. Endometriosis, adenomyosis, ovarian pathology, pelvic floor dysfunction, and uterine fibroids all sit in this category. The workup is different and the treatment is different.
Burning that persists during and after intercourse, especially with associated urinary symptoms, suggests vulvodynia, recurrent low-grade infection, or atrophic vaginitis with secondary inflammation. The treatment plan for this is not the same as for either of the above.
Pain associated with arousal failure — adequate lubrication does not develop, the tissues do not become engorged, and the discomfort is mechanical rather than inflammatory — points to vascular and hormonal contributors. Testosterone deficiency in women is the underrecognized driver here.
These four patterns have different causes and different treatments. When a clinician hands a patient a tube of lubricant without asking which one she is experiencing, the patient is usually in the wrong category for the recommendation.
The mechanism — why estrogen withdrawal hits this tissue first
The vaginal and vulvar tissues are among the most estrogen-sensitive in the body. Estrogen receptors are densely concentrated in the vaginal epithelium, the vulvar tissue, the urethra, and the bladder trigone. When circulating estradiol falls below a threshold, the consequences are predictable and rapid.
The vaginal epithelium thins from twenty-plus cell layers to four or five. Glycogen content drops, which starves the lactobacilli that maintain the acidic vaginal pH. The pH rises from 3.8 toward 5.5, shifting the microbiome and making the tissue more susceptible to inflammation and infection. Vascular density at the submucosal level decreases, reducing the engorgement response that produces lubrication and elasticity during arousal. The fibrocollagenous structure that gives the tissue elasticity stiffens.
The patient experiences this as dryness, burning, friction, urinary urgency, and recurrent UTIs that started in her late forties. The tissue exam shows pallor, loss of rugae, narrowing of the introitus, and easily friable epithelium. None of this is permanent damage. It is reversible — sometimes dramatically — when the tissue is given back the estrogen signaling it has lost.
This is the part that bothers me clinically. The treatment is well-established, well-tolerated, and supported by decades of evidence. Vaginal estrogen — delivered as a cream, ring, or insert — restores the local tissue without meaningful systemic absorption. It is safe in the vast majority of patients including most breast cancer survivors after appropriate consultation. And patients spend years suffering with a problem that responds to a six-week course.
How I evaluate someone with painful intercourse
When I see a new patient for sexual wellness, the first visit is structured around getting the differential right.
What I look for in the history:
- Time course. Did the pain start gradually with the perimenopausal transition, or abruptly after a specific event (childbirth, surgery, infection, life stressor)?
- Pain character and location. Surface versus deep, burning versus mechanical, positional versus universal.
- Cycle relationship in still-cycling women. Pain that is worse premenstrually points toward endometriosis or adenomyosis.
- Urinary symptoms. Coexisting urgency, frequency, recurrent UTIs, or urethral burning expand the differential to GSM and pelvic floor dysfunction.
- Sexual history pattern. Was arousal previously normal? Has libido shifted? What about lubrication? When did each component change?
- Medication review. SSRIs, SNRIs, antihistamines, oral contraceptives, beta-blockers, and finasteride all affect sexual function. Many patients are on something contributing to the picture.
- Prior workup. What labs have been drawn, what has been ruled out, what has been tried.
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
Lab evaluation in the comprehensive workup for painful intercourse typically includes estradiol, FSH, total and free testosterone, SHBG, DHEA-S, full thyroid panel, prolactin, and vitamin D. Urinalysis and culture if there is any urinary component. Pelvic ultrasound when the history suggests structural pathology.
The physical exam matters and is part of the visit. Tissue inspection, gentle palpation, and assessment of pelvic floor muscle tone change the differential in ways that history alone cannot capture.
What treatment actually looks like — by mechanism
The treatment plan follows the mechanism, not the symptom.
For genitourinary syndrome of menopause: vaginal estrogen, typically delivered as estradiol cream applied two to three nights weekly after an initial loading phase. Tissue restoration begins within two to four weeks, with full effect at six to twelve weeks. For patients who cannot or will not use estrogen, vaginal DHEA (prasterone) and the SERM ospemifene are alternatives. Adjunctive treatments — moisturizers, water-based lubricants for intercourse — supplement but do not replace the tissue restoration work.
For broader hormonal contributors including testosterone deficiency affecting libido and arousal: hormone optimization including low-dose testosterone, which is appropriate in many mid-life women despite the absence of an FDA-approved formulation. The clinical evidence supporting this use is strong; the prescribing pattern is increasingly established.
For tissue-quality issues that do not fully resolve with hormonal restoration alone: the O-Shot uses platelet-rich plasma injected into specific anatomic sites to support tissue regeneration. The mechanism involves growth factor release driving collagen remodeling, microvascular regeneration, and local tissue thickening. It is not a substitute for hormonal restoration; it is an adjunct when hormones are restored and the tissue still needs support.
For pelvic floor dysfunction: pelvic floor physical therapy with a qualified specialist. This is one of the most effective and most underutilized interventions in this space. We refer when the exam supports it.
For vascular contributors in male partners that are part of the painful-intercourse picture (because dyspareunia is rarely a single-partner problem): men's hormone therapy when low testosterone is documented, ED treatment when the vascular contribution is primary.
How regenerative treatments fit and when they make sense
The O-Shot has become a frequently asked-about treatment, partly because the marketing has been loud and partly because the underlying mechanism is real. I use it selectively. The patients who benefit most are those whose hormonal picture has been addressed (or is being addressed in parallel), whose tissue is still showing limitations after hormonal restoration, and whose goals include both functional and sensitivity improvements.
A typical course is one initial treatment with a follow-up at three months to assess response. Some patients need a second treatment; many do not. The full effect develops over eight to twelve weeks as tissue regeneration occurs.
What I do not do is offer the O-Shot as a stand-alone product to a patient who has not had her hormones evaluated. Treating a tissue-quality symptom without addressing an underlying estrogen deficiency that produced it is the kind of work that disappoints patients. The order matters.
What I tell middle Georgia patients about this conversation
The patients I see in Columbus, Warner Robins, and across middle Georgia frequently arrive having spent years not bringing this up to anyone. Some have been told by faith communities or family culture that this is private and not appropriate to discuss. Some have been dismissed by clinicians who did not know what to do with the complaint. Some have been told by their partners that the problem is theirs.
What I tell them is this: the consultation is private, the documentation is held to the same standard as every other medical record, and the workup is structured to produce a real answer. The military-affiliated population around Fort Benning has additional considerations around timing relative to deployment, partner availability, and the operational tempo that often delays this kind of care. We work around all of that.
The clinical next step
If you have been holding off on this conversation for months or years, the structured first visit is the move. Book a private consultation at either the Columbus or Warner Robins location, bring whatever lab work you have, write down the pain character and time course before the visit so you do not have to reconstruct it under pressure, and bring the medication list. We will run the workup that should have been run years ago, build the treatment plan from the mechanism the labs and exam reveal, and start with the conservative tissue restoration that resolves most cases before any procedural treatment is even on the table.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.